Iclusig ponatinib Tablets

Iclusig (ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. ICLUSIG (ponatinib) tablets should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

What is ICLUSIG used for?

Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Storage and Handling

Iclusig tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30° C (59° to 86° F)